Glimepiride Tablets recalled due to manufacturing practice deviations
Amerisource Health Services is recalling 105,361 bottles of Glimepiride Tablets nationwide following FDA discovery of manufacturing practice deviations. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall following discovery of Current Good Manufacturing Practice deviations. No illnesses or injuries have been reported, but CGMP violations represent potential risks to drug quality and safety.
Plain-English summary
Amerisource Health Services LLC is recalling 105,361 bottles of Glimepiride Tablets, USP, 2 mg, a prescription medication distributed nationwide. The recall was initiated following FDA discovery of Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility.
The affected medication was manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India. The recall includes multiple batches with expiration dates ranging from May 2023 through July 2025.
Consumers with prescriptions for this medication should contact their healthcare provider or pharmacist to determine if their supply contains affected batches. Patients should not discontinue their medication without consulting their doctor. No illnesses or injuries related to this recall have been reported.
The recalled product
- Product
- Glimepiride Tablets, USP, 2 mg, RX, Packaged as a ) 100-count bottle, NDC# 68001-178-00; b) 500-count bottle; NDC# 68001-178-03 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. For BluePoint Laboratories
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug
- Hazard
- Affected units
- 105,361
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Batches a)P2003493
- EXP 05/31/2023
- P2100120
- EXP 11/30/2023
- P2100683
- EXP 01/31/2024
- P2106002
- EXP 07/31/2024
- R2200148
- EXP 12/31/2024
- R2201125
- EXP 06/30/2025 b) P2003403
- b) P2005800
- EXP 09/30/2023
- P2101156
- P2105401
- R2200083
- R2201004
- EXP 07/31/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Amerisource Health Services LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09